Home
Clinical Trials
Primary Antimicrobial Resista...

Primary Antimicrobial Resistance Patterns of Austrian Helicobacter Pylori Clinical Isolates

Last Updated: 2016-10-05

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Helicobacter pylori infects \~ 50% of the world's population and a quarter of the European population. H. pylori is responsible for a large proportion of gastric and duodenal ulcers and gastritis. Chronic infection with H. pylori is a risk factor for the development of stomach cancer and MALT (mucosa-associated lymphoid tissue) Lymphoma. The prospects of success for an antimicrobial eradication therapy is drastically reduced by the significant increase in antibiotic resistance in Austrian H. pylori isolates. The currently available data were obtained however from narrowly defined geographical regions and the clinical routine without information on patient selection. We suspect a considerable geographical variability of resistance patterns and a clinical bias for a preferential investigation of patients with unsuccessful, empirical eradication therapy. The objective of the proposed study is therefore an Austria-wide collection of data on H. pylori resistance in a prospective clinical study. The data thus collected will enable a significant improvement in current treatment recommendations.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Helicobacter Pylori Resistance

NCT05019586

Helicobacter Pylori Resistance

COMPLETED

Intraluminal Therapy for Helicobacter Pylori Infection

NCT03124420

Helicobacter Pylori Infection

COMPLETED PHASE4

Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection

NCT02934048

Therapeutic Duration Helicobacter Pylori Antimicrobial Susceptibility Test +1 more

UNKNOWN PHASE4

H. Pylori Screen-and-treat Study in a Population of Young Adults

NCT06275204

Gastric Cancer H Pylori Infection H Pylori Eradication +1 more

RECRUITING

Intraluminal Metronidazole Powder Monotherapy for Helicobacter Pylori Infection

NCT03524833

Helicobacter Pylori Infection

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Helicobacter Pylori Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Undergoing a diagnostic gastroscopy for the first time in their lives or had a diagnostic gastroscopy for any reason \>10 years ago
* Older than 18 years of age
* Written informed consent

Exclusion Criteria

* Previous H. pylori eradication therapies
* Antimicrobial treatment for other reasons than H. pylori eradication within 3 months prior to gastroscopy

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers